Abstracts Archive - Page 1952 of 2607 - ACR Meeting Abstracts

Abstract Number: 1214 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis in Female Spouses in the Agricultural Health Study: Associations with Pesticides and Other Farm Exposures
Christine G. Parks¹, Jane Hoppin², Karen H. Costenbader³ and Dale Sandler⁴, ¹Epidemiology Branch, National Institute of Environmental Health Science, Research Triangle Park, NC, ²Biological Sciences, North Carolina State University, Raleigh, NC, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Epidemiology Branch, NIH/NIEHS, Research Triangle Park, NC
Background/Purpose: Farming has been associated with rheumatoid arthritis (RA), but the role of pesticides is not known. We examined associations between RA, pesticides and other…
Abstract Number: 1215 • 2015 ACR/ARHP Annual Meeting
Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis
Gavin Sun¹, Glen Hazlewood², Sasha Bernatsky³, Gilaad Kaplan⁴, Bertus Eksteen⁵ and Cheryl Barnabe², ¹Department of Internal Medicine, University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Division of Hepatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases, including rheumatoid arthritis (RA),…
Abstract Number: 1216 • 2015 ACR/ARHP Annual Meeting
The Clinical and Ultrasonographic Presentation of Seronegative RA Is More Severe Compared to Seropositive RA in an Inception Cohort of DMARD-Naïve Patients Classified According to the 2010 ACR/EULAR Criteria
Lena B. Nordberg¹, Siri Lillegraven¹, Elisabeth Lie¹, Anna-Birgitte Aga², Inge C Olsen², Hilde Berner Hammer³, Till Uhlig¹, Désirée van der Heijde⁴, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The development of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) has led to a redefinition of the patient population, including classification of…
Abstract Number: 1217 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jeffrey A. Sparks¹, Boris Hejblum², I-Hsin Kuo¹, Jing Cui¹, Lauren J. Lahey³, Andrew Cagan⁴, Vivian Gainer⁴, Weidong Liu⁵, Tony Cai⁶, Jeremy Sokolove⁷ and Tianxi Cai², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Biostatistics, Harvard School of Public Health, Boston, MA, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Research Computing, Partners HealthCare, Charlestown, MA, ⁵Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China, ⁶Statistics, University of Pennsylvania, Philadelphia, PA, ⁷Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: RA patients develop autoantibodies against a spectrum of antigens. However, the clinical significance of these autoantibodies after RA diagnosis is unclear. The Phenome-Wide Association…
Abstract Number: 1218 • 2015 ACR/ARHP Annual Meeting
Higher Education Is Associated with a Better Rheumatoid Arthritis Outcome Concerning Pain and Function but Not Disease Activity: Results from Swedish Registers
Xia Jiang¹, Maria Sandberg², Saedis Saevarsdottir³, Lars Alfredsson⁴, Lars Klareskog⁵ and Camilla Bengtsson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Unit of Cardiovascular Epidemiology, Institute of Enviornmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁶The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To investigate the influence of education (achieving university/college degree (high) or not (low)) on the outcomes of early RA, in terms of disease activity,…
Abstract Number: 1219 • 2015 ACR/ARHP Annual Meeting
Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Poland: First Nationwide Study
Bogdan Batko¹, Marcin Stajszczyk², Jerzy Swierkot³, Filip Raciborski⁴ and Piotr Wiland³, ¹Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland, ²Department of Reumatology and Autoimmune Diseases, Silesian Rheumatology Center, Ustron, Poland, ³Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ⁴Department of Epidemiology and Health Promotion, Institute of Rheumatology, Warsaw, Poland
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in Europe varies from a geographical standpoint. Knowledge of the occurrence of RA is valuable for policy makers…
Abstract Number: 1220 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Rachel J Black^1,2, Rebecca M Joseph^3,4, Mohammad Movahedi², Mark Lunt² and William G Dixon^2,5, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁵Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA). Although GPs don’t typically alter DMARD prescriptions, changes to GC therapy…
Abstract Number: 1221 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea
Yoon-Kyoung Sung¹, Soo-Kyung Cho¹, Soyoung Won², Chan-Bum Choi³, So-Young Bang⁴, Seung-Jae Hong⁵, Hyoun-Ah Kim⁶, Eunmi Koh⁷, Hye-Soon Lee⁸, Chang-Hee Suh⁹, Dae-Hyun Yoo¹⁰, Sang-Cheol Bae¹ and BIOPSY investigators, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Hanyang University Guri Hospital, Guri, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea, ⁶Ajou University Hospital, Suwon, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁹Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Recently biosimilar infliximab was approved in South Korea and it has been commonly used for rheumatoid arthritis (RA) patients who are resistant to conventional…
Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting
The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Soo-Kyung Cho¹, Dam Kim¹, Hye-Jin Jeong², Il Woong Sohn², Soyoung Won³, Minkyung Han³, Jiyoung Lee³, Eun Jin Jang⁴, Sang-Cheol Bae¹ and Yoon-Kyoung Sung¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Information Statistics, Andong National University, Andong-si, South Korea
Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
Abstract Number: 1224 • 2015 ACR/ARHP Annual Meeting
Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases
Sintawat Wangsiricharoen¹, Colin Ligon², Ahmad Dehrab³, Lydia Gedmintas⁴, Marisa Tungsiripat⁵, Clifton Bingham⁶, Carlos J. Lozada⁷ and Leonard H. Calabrese⁸, ¹Chiang Mai University, Chiang Mai, Thailand, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University of Miami Jackson Memorial Hospital, Miami, FL, ⁴Rheumatology, Brigham's Women's Hospital, Boston, MA, ⁵Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Miami Miller School of Medicine, Miami, FL, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Few HIV-infected patients have been treated with tumor necrosis factor (TNF)-α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety…
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 1226 • 2015 ACR/ARHP Annual Meeting
Assessing the Possible Association of Anti-TNF Use with New Neoplasms: An Important Methodological Consideration
Yesim Ozguler¹, Yusuf Yazici², Gulen Hatemi¹ and Hasan Yazici³, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
Background/Purpose: Whether anti- TNF agents increase the frequency of neoplasms remains debated. The drug regulatory agencies still mandate black boxes on the related package inserts…
Abstract Number: 1227 • 2015 ACR/ARHP Annual Meeting
Discrepancies Between Registered and Published Primary Outcomes in Randomized Controlled Trials of Rheumatoid Arthritis
Sheila Lezcano¹, Saha Sajib², Ashley Fan³, Mohini Pathria³, Karina Marianne D. Torralba⁴ and Nasim A. Khan⁵, ¹Internal Medicine, Loma Linda University, Loma Linda, CA, ²Internal Medicine, University of California-Riverside, Riverside, CA, ³Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ⁵Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Selective outcome reporting may bias treatment effect estimates of clinical trials. Registration of clinical trials was established to improve transparency in their conduct and…
Abstract Number: 1228 • 2015 ACR/ARHP Annual Meeting
Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink
Julian Gardiner¹, Bowen Su¹, Benjamin Ellis² and Michael Soljak¹, ¹Department of Primary Care and Public Health, Imperial College London, London, United Kingdom, ²Arthritis Research UK, London, United Kingdom
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in primary care electronic health records (EHRs) is much lower than patient self-reports from population surveys, which may…
Abstract Number: 1229 • 2015 ACR/ARHP Annual Meeting
Regional Variation in Measured Detection of Ankylosing Spondylitis
Jason Shafrin¹, Jin Joo Shim¹, Caroline Huber¹, Jenny Griffith², Arijit Ganguli² and Wade Aubry³, ¹Precision Health Economics, Los Angeles, CA, ²AbbVie Inc., North Chicago, IL, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Patients suffering from ankylosing spondylitis (AS) often receive a delayed or mis-diagnosis, as this condition is frequently confused with mechanical back pain from other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].